Zivo reaffirms former CEO Andrew Dahl was terminated for cause, disputes his email claims

Zivo Bioscience, Inc.

Company states Board terminated Andrew Dahl for cause; he was offered chance to resign before termination.
Dahl's email (Exhibit 17) challenged company's account; Company maintains its initial filing was accurate.
Company confirms it filed original 8-K and this amendment within SEC-prescribed timelines.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Andrew Dahl

Chief Executive Officer and President

ZIVO · Zivo Bioscience, Inc.

Filed: March 1, 2022, 6:59 PM ET

The Company reaffirms that the Board terminated Dahl for cause.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Andrew Dahl was terminated as Chief Executive Officer and President at Zivo Bioscience, Inc..

Action: terminated
Role: Chief Executive Officer and President

Exact text from the filing

The Company reaffirms that the Board terminated Dahl for cause.

View on SEC.gov

Zivo Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001654954-22-002336

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.